GILD · Earnings call · 2026Q3T · Full report
Operating Expense Trends
GILEAD SCIENCES, INC. · 2026-10-29 · Importance 29 · Surprise 22 · In source text
Third-quarter non-GAAP R&D expense was $1.6 billion, up 19% year over year and 11% sequentially. Management attributed the R&D increase to higher compensation accruals related to year-to-date financial outperformance and higher clinical costs. SG&A expense was $1.5 billion, up 14% year over year, reflecting HIV promotional activity, legal expenses and higher compensation accruals. For full-year 2026, Gilead expects R&D expense to increase by a mid- to high-single-digit percentage and SG&A expense by a high-single-digit percentage versus 2025.
Key facts
- Gilead expected full-year 2026 R&D expenses to increase by a mid- to high-single-digit percentage and SG&A expenses to increase by a high-single-digit percentage compared with 2025.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | — | Gilead expected full-year 2026 R&D expenses to increase by a mid- to high-single-digit percentage and SG&A expenses to increase by a… |
| operating_income | negative | committed | — | Gilead expected full-year 2026 R&D expenses to increase by a mid- to high-single-digit percentage and SG&A expenses to increase by a… |